Kymera Therapeutics (KYMR) shares were down 7.6% in Monday trading after RBC downgraded the stock to sector perform from outperform and raised its price target to $115 from $106 with speculative risk.
Intraday trading volume stood at about 533,000 shares against a daily average of over 790,000 shares.
Price: 110.31, Change: -9.04, Percent Change: -7.58
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.